Received: 26 April 2021
Accepted: 29 April 2021
First Online: 22 May 2021
: DGA declares grants from the Regional Health Administration and International Headache Society; honoraria for reviewing manuscripts for the review from the World Health Organization; travel support from Teva, Lilly, Novartis and Allergan; participation in advisory board from Allergan; membership of the Spanish Society of Neurology executive board. Only the WHO payment is related with the present work. NO declares grants from Michael J Fox Foundation for Parkinson’s disease research and Tertiary Education Trust Fund (National Research Fund); payment or honoraria from International Parkinson and Movement Disorders Society Speaker Honorarium; support from International Parkinson and Movement Disorder Society support for attending meetings; leadership as Chairperson of Africa Section of Steering Committee, International Parkinson and Movement Disorder Society. DS declares grants or contracts from National Institutes of Neurological Disorders and Stroke; national Multiple Sclerosis Society, National Institutes of Mental Health, and American Academy of Neurology, not related with this work; payment honoraria for lectures for Medlink Neurology and member as Multiple Sclerosis International Federation Global Access Working Group. AP declares payment for lectures honoraria from Abbvie, Biomarin, Chiesi, Nutricia, UCB, Zambon pharmaceuticals.
: All authors approved the final version of the manuscript. The manuscript underwent WHO Publication Review Committee clearance.